Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.

Abstract excerpt

Innovation and new molecular entity production by the pharmaceutical industry has been below expectations. Surprisingly, more first-in-class small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1999 and 2008 were identified by functional phenotypic lead generation strategies reminiscent of pre-genomics pharmacology than contemporary molecular targeted strategies that encompass the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biological Assay
• Share to Drug Discovery
• Share to Drug Industry